0000897101-17-000185.txt : 20170207 0000897101-17-000185.hdr.sgml : 20170207 20170207165118 ACCESSION NUMBER: 0000897101-17-000185 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20161231 FILED AS OF DATE: 20170207 DATE AS OF CHANGE: 20170207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Electromed, Inc. CENTRAL INDEX KEY: 0001488917 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 411732920 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34839 FILM NUMBER: 17579752 BUSINESS ADDRESS: STREET 1: 500 SIXTH AVENUE NW CITY: NEW PRAGUE STATE: MN ZIP: 56071 BUSINESS PHONE: 952-758-9299 MAIL ADDRESS: STREET 1: 500 SIXTH AVENUE NW CITY: NEW PRAGUE STATE: MN ZIP: 56071 10-Q 1 elmd170271_10q.htm FORM 10-Q FOR THE QUARTER ENDED DECEMBER 31, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☑

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2016

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________.

Commission File No.: 001-34839

Electromed, Inc.

(Exact Name of Registrant as Specified in its Charter)

Minnesota		41-1732920
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

500 Sixth Avenue NW New Prague, Minnesota		56071
(Address of principal executive offices)		(Zip Code)

(952) 758-9299

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐ (Do not check if smaller reporting company)	Smaller reporting company ☑

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

There were 8,230,167 shares of Electromed, Inc. common stock, par value $0.01, outstanding as of the close of business on February 3, 2017.

Electromed, Inc.
Index to Quarterly Report on Form 10-Q

		Page

PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements	1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	9
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	14
Item 4.	Controls and Procedures	14

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	15
Item 1A.	Risk Factors	15
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	15
Item 3.	Defaults Upon Senior Securities	15
Item 4.	Mine Safety Disclosures	15
Item 5.	Other Information	15
Item 6.	Exhibits	15

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

Electromed, Inc.

Condensed Balance Sheets

	December 31, 2016		June 30, 2016
	(Unaudited)
Assets
Current Assets
Cash	$	4,821,504	$	5,123,355
Accounts receivable (net of allowances for doubtful accounts of $45,000)		8,284,895		7,611,437
Inventories		2,570,850		2,480,443
Prepaid expenses and other current assets		425,855		419,616
Income tax receivable		2,896		192,685
Total current assets		16,106,000		15,827,536
Property and equipment, net		3,381,803		3,375,189
Finite-life intangible assets, net		776,091		904,033
Other assets		112,058		127,759
Deferred income taxes		330,000		343,000
Total assets	$	20,705,952	$	20,577,517

Liabilities and Shareholders’ Equity
Current Liabilities
Current maturities of long-term debt	$	49,720	$	46,309
Accounts payable		466,863		589,225
Accrued compensation		724,504		1,489,798
Warranty reserve		660,000		660,000
Other accrued liabilities		455,747		287,194
Total current liabilities		2,356,834		3,072,526
Long-term debt, less current maturities and net of debt issuance costs		1,120,856		1,146,395
Total liabilities		3,477,690		4,218,921

Commitments and Contingencies

Shareholders’ Equity
Common stock, $0.01 par value; authorized: 13,000,000 shares; 8,230,167 and
8,187,112 issued and outstanding at December 31, 2016 and June 30, 2016,		82,302		81,871
respectively
Additional paid-in capital		13,783,754		13,549,551
Retained earnings		3,362,206		2,727,174
Total shareholders’ equity		17,228,262		16,358,596
Total liabilities and shareholders’ equity	$	20,705,952	$	20,577,517

See Notes to Condensed Financial Statements.

Electromed, Inc.

Condensed Statements of Operations (Unaudited)

	For the Three Months Ended December 31,						For the Six Months Ended December 31,
	2016			2015			2016			2015
Net revenues	$	6,372,243		$	6,262,106		$	11,917,606		$	11,263,295
Cost of revenues		1,445,786			1,363,509			2,663,522			2,505,268
Gross profit		4,926,457			4,898,597			9,254,084			8,758,027

Operating expenses
Selling, general and administrative		4,096,197			3,591,934			7,784,107			6,824,653
Research and development		100,801			57,090			451,641			98,634
Total operating expenses		4,196,998			3,649,024			8,235,748			6,923,287
Operating income		729,459			1,249,573			1,018,336			1,834,740

Interest expense, net of interest income of $3,603, $2,924, $6,969 and $3,548 respectively		15,598			17,880			32,304			38,086
Net income before income taxes		713,861			1,231,693			986,032			1,796,654

Income tax expense		(270,000	)		(164,000	)		(351,000	)		(388,000	)
Net income	$	443,861		$	1,067,693		$	635,032		$	1,408,654

Income per share:
Basic	$	0.05		$	0.13		$	0.08		$	0.17
Diluted	$	0.05		$	0.13		$	0.08		$	0.17

Weighted-average common shares outstanding:
Basic		8,167,112			8,133,857			8,167,112			8,133,857
Diluted		8,426,996			8,195,389			8,440,698			8,185,196

See Notes to Condensed Financial Statements.

Electromed, Inc.

Condensed Statements of Cash Flows (Unaudited)

	Six Months Ended December 31,
	2016			2015
Cash Flows From Operating Activities
Net income	$	635,032		$	1,408,654
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		312,075			307,778
Amortization of finite-life intangible assets		60,963			61,272
Amortization of debt issuance costs		9,216			9,327
Share-based compensation expense		234,634			109,164
Deferred taxes		13,000			(288,000	)
Loss on disposal of property and equipment		–			17,117
Loss on disposal of intangible assets		111,497			7,848
Changes in operating assets and liabilities:
Accounts receivable		(673,458	)		(384,562	)
Inventories		(53,894	)		(290,582	)
Prepaid expenses and other assets		196,835			57,843
Accounts payable and accrued liabilities		(807,188	)		151,127
Net cash provided by operating activities		38,712			1,166,986

Cash Flows From Investing Activities
Expenditures for property and equipment		(267,117	)		(181,290	)
Expenditures for finite-life intangible assets		(44,518	)		(17,790	)
Net cash used in investing activities		(311,635	)		(199,080	)

Cash Flows From Financing Activities
Principal payments on long-term debt including capital lease obligations		(24,056	)		(24,046	)
Payment of deferred financing fees		(4,872	)		(13,520	)
Net cash used in financing activities		(28,928	)		(37,566	)
Net increase (decrease) in cash		(301,851	)		930,340
Cash
Beginning of period		5,123,355			3,598,240
End of period	$	4,821,504		$	4,528,580

See Notes to Condensed Financial Statements.

Electromed, Inc.
Notes to Condensed Financial Statements
(Unaudited)

Note 1. Interim Financial Reporting

Basis of presentation: Electromed, Inc. (the “Company”) develops, manufactures and markets innovative airway clearance products that apply High Frequency Chest Wall Oscillation (“HFCWO”) therapy in pulmonary care for patients of all ages. The Company markets its products in the U.S. to the home health care and institutional markets for use by patients in personal residences, hospitals and clinics. The Company also sells internationally both directly and through distributors. International sales were approximately $332,000 and $352,000 for the six months ended December 31, 2016 and 2015, respectively. Since its inception, the Company has operated in a single industry segment: developing, manufacturing and marketing medical equipment.

The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial statements and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. In the opinion of management, the accompanying unaudited condensed financial statements reflect all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations as required by Regulation S-X. Interim results of operations are not necessarily indicative of the results that may be achieved for the full year. The financial statements and related notes do not include all information and footnotes required by U.S. GAAP for annual reports. This interim report should be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016 (“fiscal 2016”).

A summary of the Company’s significant accounting policies follows:

Use of estimates: Management uses estimates and assumptions in preparing the condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its condensed financial statements include revenue recognition and the related estimation of selling price adjustments, allowance for doubtful accounts, inventory obsolescence, share-based compensation, income taxes and the warranty reserve.

Net income per common share: Net income is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using the weighted average number of common shares outstanding during the period, excluding any restricted stock awards which have not vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock options were exercised and converted into common stock at the beginning of the period, unless their effect would be anti-dilutive. Common stock equivalents excluded from the calculation of diluted earnings per share because their impact was anti-dilutive was 196,500 for the three and six months ended December 31, 2016 and 305,800 for the three and six months ended December 31, 2015.

New accounting pronouncements: In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance creating Accounting Standards Codification (“ASC”) Section 606, “Revenue from Contracts with Customers.” The new section will replace ASC Section 605, “Revenue Recognition” and creates modifications to various other revenue accounting standards for specialized transactions and industries. The section is intended to conform revenue accounting principles with a concurrently issued International Financial Reporting Standards with previously differing treatment between U.S. practice and that of much of the rest of the world, as well as to enhance disclosures related to disaggregated revenue information. Entities will have the option to apply the standard retrospectively to all prior periods presented, or to apply it retrospectively only to contracts existing at the effective date, with the cumulative effect of the standard recorded as an adjustment to beginning retained earnings. In August 2015, the FASB issued Accounting Standards Update (“ASU”) 2015-14 which delayed the effective date of the new revenue recognition guidance by one year. The updated guidance will be effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within that year. The Company is evaluating the impact of this standard on its financial statements.

In April 2015, FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs.” This standard became effective on July 1, 2016 for the Company and requires that debt issuance costs be presented as a direct deduction from the carrying amount of long-term debt on the balance sheet. The new guidance aligns the presentation of debt issuance costs with debt discounts and premiums. The Company adopted this guidance retrospectively effective as of July 1, 2016. As a result, the Company presented $10,000 of unamortized debt issuance costs that had been included in “Other assets” on its condensed balance sheet as of June 30, 2016 as a direct deduction from the carrying amounts of the related long-term debt liability.

In July 2015, FASB issued ASU 2015-11, “Inventory (Topic 330) Related to Simplifying the Measurement of Inventory,” which applies to all inventory except that which is measured using last-in, first-out (“LIFO”) or the retail inventory method. Inventory measured using first-in, first-out (“FIFO”) or average cost is within the scope of the new guidance and should be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The amendments will be effective for public business entities for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The new guidance should be applied prospectively, and earlier application is permitted as of the beginning of an interim or annual reporting period. The Company is evaluating the impact of the standard on its financial statements.

In February 2016, FASB issued ASU 2016-02, “Leases.” This standard requires the recognition of all lease transactions with terms in excess of 12 months on the balance sheet as a lease liability and a right-of-use asset (as defined in the standard). ASU 2016-02 will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with earlier application permitted. Upon adoption, the lessee will apply the new standard retrospectively to all periods presented or retrospectively using a cumulative effect adjustment in the year of adoption. The Company is currently assessing the effect the standard will have on its financial statements.

In March 2016, FASB issued ASU 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,” which reduces complexity in accounting standards related to share-based payment transactions, including, among others, (1) accounting for income taxes, (2) classification of excess tax benefits on the statement of cash flow, (3) forfeitures, and (4) statutory tax withholding requirements. The ASU will be effective for annual reporting periods beginning on or after December 15, 2016, and interim periods within those annual periods, with earlier application permitted. The Company is evaluating the impact of the standard on its financial statements.

Reclassifications: Certain items in the Company’s financial statements for fiscal 2016 have been reclassified to be consistent with the classifications adopted for the Company’s fiscal quarter ended December 31, 2016. The fiscal 2016 reclassifications are specific to the adoption of ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs” and had no impact on previously reported net income or equity.

Note 2. Inventories

The components of inventory were approximately as follows:

	December 31, 2016			June 30, 2016
Parts inventory	$	1,877,000		$	1,615,000
Work in process		149,000			165,000
Finished goods		705,000			850,000
Less: Reserve for obsolescence		(160,000	)		(150,000	)
Total	$	2,571,000		$	2,480,000

Note 3. Finite-life Intangible Assets

The carrying value of patents and trademarks includes the original cost of obtaining the patents, periodic renewal fees, and other costs associated with maintaining and defending patent and trademark rights. Patents and trademarks are amortized over their estimated useful lives, generally 15 and 12 years, respectively. During the six months ended December 31, 2016 and the year ended June 30, 2016, the Company abandoned certain domestic and foreign patents with net values of approximately $111,000 and $18,000, respectively, which was included as an expense in selling, general and administrative expense on the statements of operations. The majority of the pending patents, that were abandoned, related to the initial development of our SQL SmartVest technology and during a review of the Company’s patent portfolio it was determined that certain patents proved redundant to a subsequent SQL patent filing and were therefore abandoned. A smaller portion of expense was related to patents that covered technology that management considered outdated, and was no longer in use. Accumulated amortization was $789,000 and $820,000 at December 31, 2016 and June 30, 2016, respectively.

The activity and balances of finite-life intangible assets were approximately as follows:

	December 31, 2016			June 30, 2016
Balance, beginning	$	904,000		$	1,000,000
Additions		45,000			45,000
Abandonments		(112,000	)		(18,000	)
Amortization expense		(61,000	)		(123,000	)
Balance, ending	$	776,000		$	904,000

Note 4. Warranty Liability

The Company provides a lifetime warranty on its products to the prescribed patient for sales within the U.S. and a three-year warranty for all institutional sales and sales to individuals outside the U.S. The Company estimates the costs that may be incurred under its warranty and records a liability in the amount of such costs at the time the product is shipped. Factors that affect the Company’s warranty liability include the number of units shipped, historical and anticipated rates of warranty claims, the product’s useful life and cost per claim. The Company periodically assesses the adequacy of its recorded warranty liability and adjusts the amounts as necessary.

Changes in the Company’s warranty liability were approximately as follows:

		Six Months Ended			Fiscal Year Ended
		December 31, 2016			June 30, 2016
Beginning warranty reserve	$	660,000		$	660,000
Accrual for products sold		70,000			152,000
Expenditures and costs incurred for warranty claims		(70,000	)		(152,000	)
Ending warranty reserve	$	660,000		$	660,000

Note 5. Income Taxes

On a quarterly basis, the Company estimates its effective tax rate for the full fiscal year and records a quarterly income tax provision based on the anticipated rate. As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction. Income tax expense was estimated at approximately $351,000 and the effective tax rate was 35.6% for the six months ended December 31, 2016. Estimated income tax expense for the six months ended December 31, 2016 includes a recognized tax benefit of approximately $22,000 as a result of the lapse of the statute of limitation on uncertain tax positions, which reduced the effective tax rate by 2.2% for that period.

Income tax expense was estimated at approximately $388,000 and the effective tax rate was 21.6% for the six months ended December 31, 2015. Estimated income tax expense during the six months ended December 31, 2015 includes a current tax expense of $682,000 and a discrete tax benefit of $294,000 due primarily to the Company’s release of the full valuation allowance against all of its net U.S. federal and state deferred tax assets.

Note 6. Financing Arrangements

The Company has a credit facility that provides for a revolving line of credit and a term loan. Effective December 18, 2016, the Company renewed its $2,500,000 revolving line of credit. There was no outstanding principal balance on the line of credit as of December 31, 2016 or June 30, 2016. Interest on borrowings under the line of credit, if any, would accrue at the prime rate (3.75% at December 31, 2016) and is payable monthly. The amount eligible for borrowing on the line of credit is limited to the lesser of $2,500,000 or 57.00% of eligible accounts receivable and the line of credit expires on December 18, 2017, if not renewed. At December 31, 2016, the maximum $2,500,000 was eligible for borrowing. The line of credit is secured by a security interest in substantially all of the tangible and intangible assets of the Company.

In connection with the credit facility, the Company also has a term loan, which had an outstanding principal balance of approximately $1,178,000 at December 31, 2016 and $1,200,000 as of June 30, 2016. The term loan was refinanced effective December 18, 2016, reducing the interest rate from 5.00% to 3.88%. The unamortized debt issuance cost associated with this debt was approximately $8,000 and $10,000 as of December 31, 2016 and June 30, 2016, respectively. The term loan bears interest at 3.88%, with monthly payments of principal and interest of approximately $7,900 and a final payment of principal and interest of approximately $1,085,000 due on the maturity date of December 18, 2018. Payment obligations under the term loan are secured by a mortgage on the Company’s real property.

The documents governing the line of credit and term loan contain certain financial and nonfinancial covenants that include a minimum tangible net worth covenant of not less than $10,125,000 and restrictions on the Company’s ability to incur certain additional indebtedness or pay dividends.

Note 7. Stock-Based Compensation

The Company recorded approximately $235,000 and $109,000 of compensation expense related to current and past grants of stock options and restricted stock for the six months ended December 31, 2016 and 2015, respectively. This expense is included in selling, general and administrative expense. As of December 31, 2016, approximately $537,000 of total unrecognized compensation expense related to non-vested equity awards is expected to be recognized over a weighted average period of approximately 1.2 years.

The Company recognizes compensation expense related to share-based payment transactions in the financial statements based on the estimated fair value of the award issued. The fair value of each option is estimated using the Black-Scholes pricing model at the time of award grant. The Company estimates the expected life of options based on the expected holding period by the option holder. The risk-free interest rate is based upon observed U.S. Treasury interest rates for the expected term of the options. The Company makes assumptions with respect to expected stock price volatility based upon the volatility of its stock price. Forfeitures are estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from initial estimates. Forfeitures are estimated based on the percentage of awards expected to vest, taking into consideration the seniority level of the award recipient.

The following assumptions were used to estimate the fair value of options granted:

	Six Months Ended December 31, 2016	Fiscal Year Ended June 30, 2016
Risk-free interest rate	1.14% - 1.27%	1.40% - 1.92%
Expected term (years)	6	6
Expected volatility	100.5% - 105.8%	89.3% - 93.1%

Stock Options

The Company issued 176,500 stock options pursuant to its 2014 Stock Compensation Plan during the six months ended December 31, 2016. Stock option transactions during the six months ended December 31, 2016 are summarized as follows:

			Weighted Average
	Number of Shares		Exercise Price per Share
Outstanding at June 30, 2016		599,800		$2.62
Granted		176,500		$3.91
Exercised		–		–
Cancelled or Forfeited		–		–
Outstanding at December 31, 2016		776,300		$2.92

The intrinsic value of an option is the amount by which the fair value of the underlying stock exceeds its exercise price. At December 31, 2016, the weighted average remaining contractual term for all outstanding stock options was 5.93 years and their aggregate intrinsic value was approximately $763,000. Outstanding at December 31, 2016 were 776,300 stock options issued to employees, of which approximately 467,000 were exercisable and had an aggregate intrinsic value of approximately $508,000.

Restricted Stock

The Company’s 2014 Stock Compensation Plan permits the grant of other stock-based awards. Historically, the Company makes restricted stock grants to key employees and non-employee directors that vest over six months to three years.

During the six months ended December 31, 2016, the Company issued restricted stock awards to employees totaling 30,000 shares of common stock, with a vesting term of one to three years and a fair value of $3.82 per share and to directors totaling 13,055 shares of common stock, with a vesting term of six months and a fair value of $3.83 per share. The restricted stock’s fair value per share represents the closing price of its common stock on the date of the grant. Restricted stock transactions during the six months ended December 31, 2016 are summarized as follows:

	Number of Shares	Weighted Average Grant Date Fair Value per Share
Unvested shares at June 30, 2016	19,999	$1.80
Granted	43,055	$3.82
Vested	–	–
Forfeited	–	–
Unvested at December 31, 2016	63,054	$3.18

Note 8. Commitments and Contingencies

The Company is occasionally involved in claims and disputes arising in the ordinary course of business. The Company insures its business risks where possible to mitigate the financial impact of individual claims, and establishes reserves for an estimate of any probable cost of settlement or other disposition.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed financial statements and related notes thereto included in Item 1 of Part I of this Quarterly Report on Form 10-Q and the audited financial statements, related notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2016, or “fiscal 2016.”

Overview

Electromed, Inc. (“we,” “our,” “us,” or the “Company”) develops and provides innovative airway clearance products applying High Frequency Chest Wall Oscillation (“HFCWO”) technologies in pulmonary care for patients of all ages.

We manufacture, market and sell products that provide HFCWO, including the SmartVest^®Airway Clearance System (“SmartVest System”) that includes our newest generation SmartVest SQL^® and previous generation SV2100, and related products, to patients with compromised pulmonary function. The SmartVest SQL is smaller, quieter and lighter than our previous product, with enhanced programmability and ease of use. Our products are sold in both the home health care market and the institutional market for use by patients in hospitals, which we refer to as “institutional sales.” The SmartVest SQL has been sold in the domestic home care market since the quarter ended March 31, 2014. In the fourth quarter of fiscal 2015, we launched the SmartVest SQL into the institutional and certain international markets. Since 2000, we have marketed the SmartVest System and its predecessor products to patients suffering from cystic fibrosis, bronchiectasis and repeated episodes of pneumonia. Additionally, we offer our products to a patient population that includes neuromuscular disorders such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis (“ALS”), the combination of emphysema and chronic bronchitis commonly known as chronic obstructive pulmonary disease (“COPD”), and patients with post-surgical complications or who are ventilator dependent or have other conditions involving excess secretion and impaired mucus transport.

The SmartVest System is often eligible for reimbursement from major private insurance providers, health maintenance organizations, or “HMOs”, state Medicaid systems, and the federal Medicare system, which is an important consideration for patients considering an HFCWO course of therapy. For domestic sales, the SmartVest System may be reimbursed under the Medicare-assigned billing code for HFCWO devices if the patient has cystic fibrosis, bronchiectasis (including chronic bronchitis or COPD that has resulted in a diagnosis of bronchiectasis), or any one of certain enumerated neuro-muscular diseases, and can demonstrate that another less expensive physical or mechanical treatment did not adequately mobilize retained secretions. Private payers consider a variety of sources, including Medicare, as guidelines in setting their coverage policies and payment amounts.

Critical Accounting Policies and Estimates

For a description of our critical accounting policies, estimates and assumptions used in the preparation of our financial statements, including the condensed financial statements in this report, see Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and Note 1 to our audited financial statements, included in Part II, Item 8, of our Annual Report on Form 10-K for fiscal 2016.

Some of our accounting policies require us to exercise significant judgment in selecting the appropriate assumptions for calculating financial statements. Such judgments are subject to an inherent degree of uncertainty. These judgments are based upon our historical experience, known trends in our industry, terms of existing contracts and other information from outside sources, as appropriate. We believe the critical accounting policies that require the most significant assumptions and judgments in the preparation of our financial statements, including the condensed financial statements in this report, include: revenue recognition and the estimation of selling price adjustments, allowance for doubtful accounts, inventory obsolescence, share-based compensation, income taxes and warranty liability.

Results of Operations

Revenues

Revenue for the three and six-month periods ended December 31, 2016 and 2015 are summarized in the table below (dollar amounts in thousands).

	Three Months Ended								Six Months Ended
	December 31,				Increase				December 31,				Increase (Decrease)
	2016		2015						2016		2015
Total Revenue	$	6,372	$	6,262	$	110	1.8	%	$	11,918	$	11,263	$	655		5.8	%
Home Care Revenue		5,502		5,501		1	0.0	%		10,635		9,987		648		6.5	%
Institutional Revenue		605		529		76	14.4	%		951		924		27		2.9	%
International Revenue		265		232		33	14.2	%		332		352		(20	)	(5.7	%)

Home Care Revenue. Home care revenue for the three months ended December 31, 2016 was approximately $5,502,000, an increase of approximately $1,000 compared to the same period in fiscal 2015. For the six months ended December 31, 2016, home care revenue was approximately $10,635,000, an increase of approximately $648,000, or 6.5%, compared to the same periods in fiscal 2015. During the three months ended December 31, 2016, home care revenue was negatively impacted by the retroactive repayment of previously collected and recognized revenue to a state Medicaid program totaling approximately $212,000. The repayment resulted from the state Medicaid program’s reinterpretation of its reimbursement process and a reduction in its allowable payments. We believe that the repayment is a one-time event and is not reflective of other state Medicaid reimbursement processes. During the three months ended December 31, 2015, home care revenue benefited by approximately $250,000 from processing a backlog of referrals from the prior fiscal year in a certain state. The backlog accumulated while we reapplied for a state home medical equipment license until we met a newly imposed requirement to have an approved in-state presence. The license was reinstated in October 2015.

After taking into consideration the negative impact of the retroactive repayment during the three months ended December 31, 2016, and the favorable impact of the processing of backlogged referrals during the three months ended December 31, 2015, home care revenue for the three months ended December 31, 2016 increased primarily due to increases in both approvals and referrals. The increase in referrals was predominately due to growth in the number of field sales employees and a higher referral per field sales employee as compared to the comparable prior year period. The increase in home care revenue for the six months ended December 31, 2016 was primarily due to an increase in the average rate of reimbursement per approval and increases in approvals and referrals. The increase in referrals was primarily due to growth in the number of field sales employees as compared to the comparable prior year period.

Institutional Revenue. Institutional revenue for the three and six months ended December 31, 2016 was approximately $605,000 and $951,000, respectively, representing an increase of approximately $76,000 and $27,000, or 14.4% and 2.9%, compared to the same periods in fiscal 2015. The increase in revenue for the three months ended December 31, 2016 was primarily due a higher average selling price for devices sold compared to the same period in the prior year. The increase in revenue for the six months ended December 31, 2016 was due to an increase in sales of single patient use garments, partially offset by a decrease in the number of units sold compared to the same period in the prior year. Institutional revenue includes sales to distributors, group purchasing organization (“GPO”) members and other institutions.

International Revenue. International revenue for the three months ended December 31, 2016 was approximately $265,000, representing an increase of approximately $33,000, or 14.2%, compared to the same period in fiscal 2015. For the six months ended December 31, 2016, international revenue was approximately $332,000, a decrease of approximately $20,000, or 5.7%, from the same period in fiscal 2015. International sales are affected by the timing of distributor purchases that can cause significant fluctuations in reported revenue on a quarterly basis.

Gross profit

Gross profit increased to approximately $4,926,000, or 77.3% of net revenues, for the three months ended December 31, 2016, from approximately $4,899,000, or 78.2% of net revenues, in the same period in fiscal 2015. Gross profit increased to approximately $9,254,000, or 77.7% of net revenues, for the six months ended December 31, 2016, from approximately $8,758,000, or 77.8% of net revenues, in the same period in fiscal 2015. The increase in gross profit dollars resulted from increases in domestic home care revenues and a decrease in our manufacturing costs of the SmartVest SQL as compared to the prior fiscal year. The increases in gross profit were partially offset by a charge recognized during the three and six months ended December 31, 2016 related to the retroactive repayment of previously collected and recognized revenue to a state Medicaid program totaling approximately $212,000.

Operating expenses

Selling, general and administrative expenses. Selling, general and administrative (“SG&A”) expenses were approximately $4,096,000 and $7,784,000 for the three and six months ended December 31, 2016, respectively, representing an increase of approximately $504,000 and $959,000, or 14.0% and 14.1%, respectively, compared to the same periods in the prior year.

Payroll and compensation-related expenses were approximately $2,350,000 and $4,387,000 for the three and six months ended December 31, 2016, respectively, representing an increase of approximately $247,000 and $530,000, or 11.7% and 13.7%, respectively, compared to the same periods in the prior year. The increases in the current year periods were due to additional employees in sales and administration, additional sales incentives on higher revenue, higher share-based equity compensation expense, annual salary increases and the replacement of certain employees at increased salaries in our sales department, which were partially offset by lower management bonus accruals.

Professional fees for the three and six months ended December 31, 2016 were approximately $325,000 and $672,000, respectively, an increase of approximately $48,000 and $120,000, or 17.3% and 21.7%, respectively, compared to the same periods in the prior year. These fees are primarily for services related to legal costs, shareowner services and reporting requirements, information technology (“IT”) security and backup, and consulting fees for sales training. The increase in professional fees was primarily due to increases in consulting fees associated with sales training and investor relations costs.

Recruiting fees for the three and six months ended December 31, 2016 were approximately $87,000 and $158,000, respectively, an increase of approximately $35,000 and $72,000, or 67.3% and 83.7%, respectively, compared to the same period in the prior year. The increase in recruiting fees was due primarily to adding more employees in sales and administrative roles as compared to the prior year.

Travel, meals and entertainment expenses were approximately $398,000 and $817,000 for the three and six months ended December 31, 2016, respectively, representing an increase of approximately $63,000 and $125,000, or 18.8% and 18.1%, respectively, compared to the same periods in the prior year. The increase was due primarily to additional sales personnel.

SG&A expenses included a loss on the abandonment of certain domestic and foreign patents with net values of approximately $111,000 during both the three and six months ended December 31, 2016 as compared to zero and $8,000 recognized during the three and six months ended December 31, 2015, respectively.

In addition, SG&A expenses did not include medical device excise tax for the three and six months ended December 31, 2016, representing a decrease of approximately $66,000 and $132,000, respectively, compared to the same periods in the prior year. Beginning with the third quarter of fiscal 2016, we realized a positive impact to operating profit with the Federal Consolidated Appropriations Act, 2016, which included a two-year moratorium on the U.S. Federal medical device excise tax effective as of January 1, 2016.

Research and development expenses. Research and development (“R&D”) expenses were approximately $101,000 and $452,000 for the three and six months ended December 31, 2016, respectively, representing an increase of approximately $44,000 and $353,000 compared to the same periods in the prior year. R&D expenses for the three and six months ended December 31, 2016 were 1.6% and 3.8% of revenue, respectively, compared to 0.9% of revenue for both periods in the prior year. During Fiscal 2016, we began developing a new wireless connectivity feature for our HFCWO device that will allow data connection between physicians and patients. We believe this innovation will strengthen our patient and clinician partnerships, leading to greater therapy adherence and improved quality of life for individuals with compromised pulmonary function. We expect to launch the new feature by end of fiscal 2017. We believe that R&D expense over the next few quarters will decrease as we have concluded the majority of work on our wireless data connectivity project but would expect expenses to increase in future quarters as we initiate new projects. During the quarter ended December 31, 2016, we capitalized an additional $190,000 related to software development in conjunction with this project.

Interest expense

Interest expense, net, was approximately $16,000 and $32,000 for the three and six months ended December 31, 2016, respectively, compared to $18,000 and $38,000 in the same periods in the prior year due to lower levels of long-term debt and increased interest income.

Income tax expense

Income tax expense was estimated at approximately $270,000 and $351,000 and the effective tax rates were 37.8% and 35.6%, respectively, for the three and six months ended December 31, 2016. Estimated income tax expense for the six months ended December 31, 2016 includes a recognized tax benefit of approximately $22,000 as a result of the lapse of the statute of limitation on uncertain tax positions, which reduced the effective tax rate by 2.2% for that period.

Income tax expense was estimated at approximately $164,000 and $388,000 and the effective tax rates were 13.3% and 21.6%, respectively, for the three and six months ended December 31, 2015. Income tax expense during the three and six months ended December 31, 2015 includes a current tax expense of $458,000 and $682,000, respectively, and a discrete tax benefit of $294,000 due primarily to the Company’s release of the full valuation allowance against all of its net U.S. federal and state deferred tax assets. The discrete tax benefit reduced the effective tax rate by 23.9% and 16.4% during the three and six months ended December 31, 2015, respectively.

Net income

Net income for the three and six months ended December 31, 2016 was approximately $444,000 and $635,000, respectively, compared to net income of approximately $1,068,000 and $1,409,000 for the same periods in the prior year. The year-over-year decrease in net income was driven primarily by increased payroll and compensation expenses in sales and administrative positions and increased research and development costs, which were partially offset by increased in gross profit driven by higher revenue. Additionally, the prior year benefited by a discrete tax benefit of $294,000 during the three and six months ended December 31, 2015.

Liquidity and Capital Resources

Cash Flows and Sources of Liquidity

Cash Flows from Operating Activities

For the six months ended December 31, 2016, net cash provided by operating activities was approximately $39,000. Cash flows provided by operating activities consisted of approximately $635,000 of net income, non-cash expenses of $741,000 and a decrease in prepaid expenses and other assets of $197,000. These cash flows from operating activities were offset by a decrease of approximately $807,000 in accounts payable and accrued liabilities, an increase in accounts receivable of $673,000 and an increase in inventory of $54,000.

For the six months ended December 31, 2015, net cash provided by operating activities was approximately $1,167,000. Cash flows provided by operating activities consisted of approximately $1,409,000 in net income, non-cash expenses of approximately $225,000, a decrease in prepaid expenses and other assets of approximately $58,000, and an increase in accounts payable and accrued liabilities of approximately $151,000. This was offset by an increase in accounts receivable and inventories of approximately $385,000 and $291,000, respectively.

Cash Flows from Investing Activities

For the six months ended December 31, 2016, cash used in investing activities was approximately $312,000. Cash used in investing activities consisted of approximately $267,000 in expenditures for property and equipment and $45,000 in payments for patent costs. The expenditures for property and equipment consisted primarily of costs associated with the development of software associated with the new wireless connectivity feature for our HFCWO device.

For the six months ended December 31, 2015, cash used in investing activities was approximately $199,000. Cash used in investing activities consisted of approximately $181,000 in expenditures for property and equipment and $18,000 in payments for patent costs.

Cash Flows from Financing Activities

For the six months ended December 31, 2016, cash used in financing activities was approximately $29,000, which consisted of principal payments on long-term debt of $24,000, and payments of deferred financing fees of $5,000.

For the six months ended December 31, 2015, cash used in financing activities was approximately $38,000, which consisted of principal payments on long-term debt of $24,000, and payments of deferred financing fees of $14,000.

Adequacy of Capital Resources

Our primary working capital requirements relate to adding employees to our sales force and support functions, continuing research and development efforts, and supporting general corporate needs, including financing equipment purchases and other capital expenditures incurred in the ordinary course of business. Based on our recent operational performance, we believe our working capital of approximately $13,749,000 as of December 31, 2016 and available borrowings under our existing credit facility will provide adequate liquidity for the next year.

Effective December 18, 2016, we renewed our credit facility, which provides us with a revolving line of credit and a term loan. Interest on borrowings on the line of credit accrues at the prime rate and is payable monthly. The amount eligible for borrowing on the line of credit is limited to the lesser of $2,500,000 or 57.00% of eligible accounts receivable, and the line of credit expires on December 18, 2017, if not renewed. At December 31, 2016, the maximum $2,500,000 was available under the line of credit and the applicable interest rate (the prime rate) was 3.75%. Payment obligations under the line of credit are secured by a security interest in substantially all of our tangible and intangible assets.

The documents governing our line of credit and term loan contain certain financial and nonfinancial covenants that include a minimum tangible net worth of not less than $10,125,000 and restrictions on our ability to incur certain additional indebtedness or pay dividends. We were in compliance with these covenants as of December 31, 2016.

Any failure to comply with these covenants in the future may result in an event of default, which if not cured or waived, could result in the lender accelerating the maturity of our indebtedness, preventing access to additional funds under the line of credit and/or term loan, requiring prepayment of outstanding indebtedness under either arrangement, or refusing to renew the line of credit. If the maturity of the indebtedness is accelerated or the line of credit is not renewed, sufficient cash resources to satisfy the debt obligations may not be available and we may not be able to continue operations as planned. The indebtedness under the line of credit and term loan are secured by a security interest in substantially all of our tangible and intangible assets and a mortgage on our real property, respectively. If we are unable to repay such indebtedness, the lender could foreclose on these assets.

For the six months ended December 31, 2016 and 2015, we spent approximately $267,000 and $181,000, respectively, on property and equipment. We currently expect to finance planned equipment purchases with cash flows from operations or borrowings under our credit facility. We may need to incur additional debt if we have an unforeseen need for additional capital equipment or if our operating performance does not generate adequate cash flows.

Off-Balance Sheet Arrangements

As of December 31, 2016, we had no off-balance sheet arrangements.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this Quarterly Report on Form 10-Q that are not statements of historical fact should be considered forward-looking statements within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements include, but are not limited to, statements regarding the following: our business strategy, including our intended level of investment in research and development and marketing activities; our expectations with respect to earnings, gross margins and sales growth, industry relationships, marketing strategies and international sales; our business strengths and competitive advantages; our plans and expectations with respect to international sales growth; our intent to retain any earnings for use in operations rather than paying dividends; our expectation that our products will continue to qualify for reimbursement and payment under government and private insurance programs; our intellectual property plans and practices; the expected impact of applicable regulations on our business; our beliefs about our manufacturing processes; our expectations and beliefs with respect to our employees and our relationships with them; our belief that our current facilities are adequate to support our growth plans; our expectations with respect to ongoing compliance with the terms of our credit facility; our expectations regarding the ongoing availability of credit and our ability to renew our line of credit; and our anticipated revenues, expenses, capital requirements and liquidity. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “ongoing,” “plan,” “potential,” “project,” “should,” “target,” “will,” “would,” and similar expressions, including the negative of these terms, are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Although we believe these forward-looking statements are reasonable, they involve risks and uncertainties that may cause actual results to differ materially from those projected by such statements. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results or our industry’s actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements.

Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to:

●

the competitive nature of our market;

●

changes to Medicare, Medicaid, or private insurance reimbursement policies;

●

changes to health care laws;

●

changes affecting the medical device industry;

●

our need to maintain regulatory compliance and to gain future regulatory approvals and clearances;

●

new drug or pharmaceutical discoveries;

●

general economic and business conditions;

●

our ability to renew our line of credit or obtain additional credit as necessary;

●

our ability to protect and expand our intellectual property portfolio; and

●

the risks associated with expansion into international markets.

This list of factors is not exhaustive, however, and these or other factors, many of which are outside of our control, could have a material adverse effect on us and our results of operations. Therefore, you should consider these risk factors with caution and form your own critical and independent conclusions about the likely effect of these risk factors on our future performance. Forward-looking statements speak only as of the date on which the statements are made, and we undertake no obligation to update any forward-looking statement for any reason, even if new information becomes available or other events occur in the future. You should carefully review the disclosures and the risk factors described in this and other documents we file from time to time with the Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K and subsequent reports we file with the SEC. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth herein.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide disclosure pursuant to this Item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our principal executive officer and principal financial officer evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act, as of the end of the period subject to this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of the date of such evaluation to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms.

Changes to Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the three months ended December 31, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

Occasionally, we may be party to legal actions, proceedings, or claims in the ordinary course of business, including claims based on assertions of patent and trademark infringement. Corresponding costs are accrued when it is probable that loss will be incurred and the amount can be precisely or reasonably estimated. We are not aware of any undisclosed actual or threatened litigation that would have a material adverse effect on our financial condition or results of operations.

Item 1A. Risk Factors.

As a smaller reporting company, we are not required to provide disclosure pursuant to this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

None.

Item 5. Other Information.

None.

Item 6. Exhibits.

The Exhibit Index following the signature page to this report is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		ELECTROMED, INC.

Date: February 7, 2017		/s/ Kathleen S. Skarvan
		Kathleen S. Skarvan, President and Chief Executive Officer (duly authorized officer)

Date: February 7, 2017		/s/ Jeremy T. Brock
		Jeremy T. Brock, Chief Financial Officer
		(principal financial officer and principal accounting officer)

EXHIBIT INDEX

Electromed, Inc.

Form 10-Q

Unless otherwise indicated, all documents incorporated into this Quarterly Report on Form 10-Q by reference to a document filed with the SEC pursuant to the Exchange Act are located under SEC file number 001-34839.

Exhibit Number	Description	Method of Filing
3.1	Composite Articles of Incorporation, as amended through November 8, 2010 (incorporated by reference to Exhibit 3.1 to Annual Report on Form 10-K for the fiscal year ended June 30, 2015)	Incorporated by Reference

3.2	Composite Bylaws, as amended through June 30, 2012 (incorporated by reference to Exhibit 3.2 to Annual Report on Form 10-K for the fiscal year ended June 30, 2015)	Incorporated by Reference

10.1	Business Loan Agreement (Asset Based) with Venture Bank, dated December 18, 2016 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed December 16, 2016)	Incorporated by Reference

10.2	Rider to Business Loan Agreement (Asset Based) with Venture Bank, dated December 18, 2016 (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed December 16, 2016)	Incorporated by Reference

10.3	Change in Terms Agreement with Venture Bank, dated December 18, 2016 (incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed December 16, 2016)	Incorporated by Reference

10.4	Business Loan Agreement with Venture Bank, dated December 18, 2016 (incorporated by reference to Exhibit 10.4 to Current Report on Form 8-K filed December 16, 2016)	Incorporated by Reference

10.5	Rider to Business Loan Agreement with Venture Bank, dated December 18, 2016 (incorporated by reference to Exhibit 10.5 to Current Report on Form 8-K filed December 16, 2016)	Incorporated by Reference

10.6	Change in Terms Agreement with Venture Bank, dated December 18, 2016 (incorporated by reference to Exhibit 10.6 to Current Report on Form 8-K filed December 16, 2016)	Incorporated by Reference

31.1	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed Electronically

31.2	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed Electronically

32.1	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed Electronically

32.2	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed Electronically

101	Financial statements from the Quarterly Report on Form 10-Q for the period ended December 31, 2016, formatted in XBRL: (i) Condensed Balance Sheets, (ii) Condensed Statements of Income, (iii) Condensed Statements of Cash Flows, and (iv) Notes to Condensed Financial Statements	Filed Electronically

EX-31.1 2 elmd170271_ex31-1.htm CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY

Exhibit 31.1

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Kathleen S. Skarvan, certify that:

I have reviewed this report on Form 10-Q of Electromed, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	February 7, 2017	/s/ Kathleen S. Skarvan
		Kathleen S. Skarvan
		President and Chief Executive Officer

EX-31.2 3 elmd170271_ex31-2.htm CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY

Exhibit 31.2

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Jeremy T. Brock, certify that:

I have reviewed this report on Form 10-Q of Electromed, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	February 7, 2017	/s/ Jeremy T. Brock
		Jeremy T. Brock
		Chief Financial Officer

EX-32.1 4 elmd170271_ex32-1.htm CERTIFICATION PURSUANT TO SECTION 906 OF SARBANES-OXLEY

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Electromed, Inc. (the “Company”) on Form 10-Q for the quarter ended December 31, 2016, as filed with the Securities and Exchange Commission (the “Report”), I, Kathleen S. Skarvan, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:	February 7, 2017	/s/ Kathleen S. Skarvan
		Kathleen S. Skarvan
		President and Chief Executive Officer

EX-32.2 5 elmd170271_ex32-2.htm CERTIFICATION PURSUANT TO SECTION 906 OF SARBANES-OXLEY

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Electromed, Inc. (the “Company”) on Form 10-Q for the quarter ended December 31, 2016, as filed with the Securities and Exchange Commission (the “Report”), I, Jeremy T. Brock, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:	February 7, 2017	/s/ Jeremy T. Brock
		Jeremy T. Brock
		Chief Financial Officer

EX-101.SCH 6 elmd-20161231.xsd XBRL SCHEMA FILE 00000001 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Interim Financial Reporting link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Finite-life Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Warranty Liability link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Financing Arrangements link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments And Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Interim Financial Reporting (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Finite-life Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Warranty Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Interim Financial Reporting (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Finite-life Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Finite-life Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Warranty Liability (Details Narratives) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Warranty Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Financing Arrangements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Stock-Based Compensation (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Stock-Based Compensation (Details 2) link:presentationLink link:calculationLink link:definitionLink EX-101.INS 7 elmd-20161231.xml XBRL INSTANCE FILE 0001488917 2016-07-01 2016-12-31 0001488917 2017-02-03 0001488917 2015-07-01 2015-12-31 0001488917 us-gaap:EmployeeStockOptionMember 2016-12-31 0001488917 2016-12-31 0001488917 2016-06-30 0001488917 us-gaap:PatentsMember 2016-07-01 2016-12-31 0001488917 us-gaap:TrademarksMember 2016-07-01 2016-12-31 0001488917 us-gaap:RevolvingCreditFacilityMember 2016-07-01 2016-12-31 0001488917 elmd:InternationalMember 2015-07-01 2015-12-31 0001488917 elmd:InternationalMember 2016-07-01 2016-12-31 0001488917 us-gaap:RestrictedStockMember us-gaap:MaximumMember 2016-07-01 2016-12-31 0001488917 us-gaap:RestrictedStockMember us-gaap:MinimumMember 2016-07-01 2016-12-31 0001488917 us-gaap:RestrictedStockMember 2016-07-01 2016-12-31 0001488917 us-gaap:RestrictedStockMember 2016-06-30 0001488917 us-gaap:EmployeeStockOptionMember 2016-06-30 0001488917 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-12-31 0001488917 us-gaap:LoansPayableMember 2016-06-30 0001488917 us-gaap:LoansPayableMember 2016-07-01 2016-12-31 0001488917 us-gaap:RestrictedStockMember 2016-12-31 0001488917 2015-06-30 0001488917 2015-12-31 0001488917 us-gaap:PatentsMember 2015-07-01 2016-06-30 0001488917 2015-07-01 2016-06-30 0001488917 us-gaap:RevolvingCreditFacilityMember 2016-12-31 0001488917 us-gaap:LoansPayableMember 2016-12-31 0001488917 us-gaap:EmployeeStockOptionMember 2015-07-01 2016-06-30 0001488917 2016-10-01 2016-12-31 0001488917 2015-10-01 2015-12-31 0001488917 elmd:RestrictedStockEmployeesMember 2016-07-01 2016-12-31 0001488917 us-gaap:RestrictedStockMember us-gaap:DirectorMember 2016-07-01 2016-12-31 0001488917 elmd:RestrictedStockEmployeesMember us-gaap:MinimumMember 2016-07-01 2016-12-31 0001488917 elmd:RestrictedStockEmployeesMember us-gaap:MaximumMember 2016-07-01 2016-12-31 iso4217:USD xbrli:shares xbrli:pure iso4217:USD xbrli:shares false --06-30 Q2 2017 2016-12-31 10-Q 0001488917 Smaller Reporting Company Electromed, Inc.

466863

589225

8284895

7611437

13783754

13549551

45000

196500

305800

196500

305800

0.01

13000000

8230167

8187112

8230167

8187112

82302

81871

724504

1489798

537000

P1Y2M12D

789000

820000

22000

45000

776091

904033

1000000

P15Y

P12Y

705000

850000

2570850

2480443

160000

150000

149000

165000

3477690

4218921

20705952

20577517

2356834

3072526

2017-12-18

49720

46309

1120856

1146395

112058

127759

455747

287194

425855

419616

660000

70000

152000

70000

152000

3381803

3375189

3362206

2727174

P3Y

P6M

P1Y

P3Y

43055

30000

13055

17228262

16358596

.356

.216

1200000

1178000

2018-12-18

Yes No No

330000

343000

2896

192685

4821504

5123355

3598240

4528580

776300

599800

176500

2.92

2.62

3.91

P5Y11M4D

763000

19999

63054

1.80

3.18

22000

1877000

1615000

112000 18000

3.82

3.18

60963

61272

123000

2500000

0.0375

2500000

0.57

10000

8000

10125000

467000

508000

10000

P3Y

1.058

.931

1.005

.893

.01140

.0140

0.0127

.0192

P6Y

-.022

8230167

6969

3548

3603

2924

16106000

15827536

20705952

20577517

111000

18000

351000

388000

270000

164000

682000

-294000

2016-12-18

0.05

.0388

7900

1085000

234634

109164

352000

332000

8440698

8185196

8426996

8195389

8167112

8133857

8167112

8133857

0.08

0.17

0.05

0.13

0.08

0.17

0.05

0.13

635032

1408654

443861

1067693

986032

1796654

713861

1231693

-32304

-38086

-15598

-17880

1018336

1834740

729459

1249573

8235748

6923287

4196998

3649024

451641

98634

100801

57090

7784107

6824653

4096197

3591934

9254084

8758027

4926457

4898597

2663522

2505268

1445786

1363509

11917606

11263295

6372243

6262106

9216

9327

312075

307778

-17117

673458

384562

53894

290582

-196835

-57843

-807188

151127

38712

1166986

13000

-288000

-311635

-199080

44518

17790

267117

181290

-301851

930340

-28928

-37566

4872

13520

24056

24046

Use of estimates: Management uses estimates and assumptions in preparing the condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its condensed financial statements include revenue recognition and the related estimation of selling price adjustments, allowance for doubtful accounts, inventory obsolescence, share-based compensation, income taxes and the warranty reserve.

Net income per common share: Net income is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using the weighted average number of common shares outstanding during the period, excluding any restricted stock awards which have not vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock options were exercised and converted into common stock at the beginning of the period, unless their effect would be anti-dilutive. Common stock equivalents excluded from the calculation of diluted earnings per share because their impact was anti-dilutive was 196,500 for the three and six months ended December 31, 2016 and 305,800 for the three and six months ended December 31, 2015.

The components of inventory were approximately as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1px solid">December 31, 2016</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1px solid"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1px solid">June 30, 2016</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1px solid"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="width: 66%; font: 10pt Times New Roman, Times, Serif; text-align: left">Parts inventory</td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 13%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,877,000</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 13%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,615,000</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Work in process</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">149,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">165,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Finished goods</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">705,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">850,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less: Reserve for obsolescence</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(160,000</td><td style="border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(150,000</td><td style="border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">Total</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,571,000</td><td style="border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,480,000</td><td style="border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

The activity and balances of finite-life intangible assets were approximately as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1px; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1px"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1px solid; text-align: center">December 31, 2016</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1px; border-bottom: Black 1px solid"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1px"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1px solid; text-align: center">June 30, 2016</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1px; border-bottom: Black 1px solid"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="width: 66%; text-align: left; font: 10pt Times New Roman, Times, Serif">Balance, beginning</td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 13%; text-align: right; font: 10pt Times New Roman, Times, Serif">904,000</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 13%; text-align: right; font: 10pt Times New Roman, Times, Serif">1,000,000</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Additions</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">45,000</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">45,000</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Abandonments</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(112,000</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(18,000</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Amortization expense</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif">(61,000</td><td style="text-align: left; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif">(123,000</td><td style="text-align: left; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="padding-bottom: 3px; font: 10pt Times New Roman, Times, Serif">Balance, ending</td><td style="padding-bottom: 3px; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif">776,000</td><td style="text-align: left; border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif"> </td><td style="padding-bottom: 3px; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif">904,000</td><td style="text-align: left; border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>

New accounting pronouncements: In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance creating Accounting Standards Codification (“ASC”) Section 606, “Revenue from Contracts with Customers.” The new section will replace ASC Section 605, “Revenue Recognition” and creates modifications to various other revenue accounting standards for specialized transactions and industries. The section is intended to conform revenue accounting principles with a concurrently issued International Financial Reporting Standards with previously differing treatment between U.S. practice and that of much of the rest of the world, as well as to enhance disclosures related to disaggregated revenue information. Entities will have the option to apply the standard retrospectively to all prior periods presented, or to apply it retrospectively only to contracts existing at the effective date, with the cumulative effect of the standard recorded as an adjustment to beginning retained earnings. In August 2015, the FASB issued Accounting Standards Update (“ASU”) 2015-14 which delayed the effective date of the new revenue recognition guidance by one year. The updated guidance will be effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within that year. The Company is evaluating the impact of this standard on its financial statements.   In April 2015, FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs.” This standard became effective on July 1, 2016 for the Company and requires that debt issuance costs be presented as a direct deduction from the carrying amount of long-term debt on the balance sheet. The new guidance aligns the presentation of debt issuance costs with debt discounts and premiums. The Company adopted this guidance retrospectively effective as of July 1, 2016. As a result, the Company presented $10,000 of unamortized debt issuance costs that had been included in “Other assets” on its condensed balance sheet as of June 30, 2016 as a direct deduction from the carrying amounts of the related long-term debt liability.    In July 2015, FASB issued ASU 2015-11, “Inventory (Topic 330) Related to Simplifying the Measurement of Inventory,” which applies to all inventory except that which is measured using last-in, first-out (“LIFO”) or the retail inventory method. Inventory measured using first-in, first-out (“FIFO”) or average cost is within the scope of the new guidance and should be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The amendments will be effective for public business entities for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The new guidance should be applied prospectively, and earlier application is permitted as of the beginning of an interim or annual reporting period. The Company is evaluating the impact of the standard on its financial statements.   In February 2016, FASB issued ASU 2016-02, “Leases.” This standard requires the recognition of all lease transactions with terms in excess of 12 months on the balance sheet as a lease liability and a right-of-use asset (as defined in the standard). ASU 2016-02 will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with earlier application permitted.  Upon adoption, the lessee will apply the new standard retrospectively to all periods presented or retrospectively using a cumulative effect adjustment in the year of adoption. The Company is currently assessing the effect the standard will have on its financial statements.   In March 2016, FASB issued ASU 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,” which reduces complexity in accounting standards related to share-based payment transactions, including, among others, (1) accounting for income taxes, (2) classification of excess tax benefits on the statement of cash flow, (3) forfeitures, and (4) statutory tax withholding requirements.  The ASU will be effective for annual reporting periods beginning on or after December 15, 2016, and interim periods within those annual periods, with earlier application permitted.  The Company is evaluating the impact of the standard on its financial statements.

-111497

-7848

Note 1.          Interim Financial Reporting   Basis of presentation: Electromed, Inc. (the “Company”) develops, manufactures and markets innovative airway clearance products that apply High Frequency Chest Wall Oscillation (“HFCWO”) therapy in pulmonary care for patients of all ages. The Company markets its products in the U.S. to the home health care and institutional markets for use by patients in personal residences, hospitals and clinics. The Company also sells internationally both directly and through distributors. International sales were approximately $332,000 and $352,000 for the six months ended December 31, 2016 and 2015, respectively. Since its inception, the Company has operated in a single industry segment: developing, manufacturing and marketing medical equipment.   The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial statements and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. In the opinion of management, the accompanying unaudited condensed financial statements reflect all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations as required by Regulation S-X. Interim results of operations are not necessarily indicative of the results that may be achieved for the full year. The financial statements and related notes do not include all information and footnotes required by U.S. GAAP for annual reports. This interim report should be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016 (“fiscal 2016”).   A summary of the Company’s significant accounting policies follows:   Use of estimates: Management uses estimates and assumptions in preparing the condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its condensed financial statements include revenue recognition and the related estimation of selling price adjustments, allowance for doubtful accounts, inventory obsolescence, share-based compensation, income taxes and the warranty reserve.   Net income per common share: Net income is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using the weighted average number of common shares outstanding during the period, excluding any restricted stock awards which have not vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock options were exercised and converted into common stock at the beginning of the period, unless their effect would be anti-dilutive. Common stock equivalents excluded from the calculation of diluted earnings per share because their impact was anti-dilutive was 196,500 for the three and six months ended December 31, 2016 and 305,800 for the three and six months ended December 31, 2015.   New accounting pronouncements: In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance creating Accounting Standards Codification (“ASC”) Section 606, “Revenue from Contracts with Customers.” The new section will replace ASC Section 605, “Revenue Recognition” and creates modifications to various other revenue accounting standards for specialized transactions and industries. The section is intended to conform revenue accounting principles with a concurrently issued International Financial Reporting Standards with previously differing treatment between U.S. practice and that of much of the rest of the world, as well as to enhance disclosures related to disaggregated revenue information. Entities will have the option to apply the standard retrospectively to all prior periods presented, or to apply it retrospectively only to contracts existing at the effective date, with the cumulative effect of the standard recorded as an adjustment to beginning retained earnings. In August 2015, the FASB issued Accounting Standards Update (“ASU”) 2015-14 which delayed the effective date of the new revenue recognition guidance by one year. The updated guidance will be effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within that year. The Company is evaluating the impact of this standard on its financial statements.   In April 2015, FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs.” This standard became effective on July 1, 2016 for the Company and requires that debt issuance costs be presented as a direct deduction from the carrying amount of long-term debt on the balance sheet. The new guidance aligns the presentation of debt issuance costs with debt discounts and premiums. The Company adopted this guidance retrospectively effective as of July 1, 2016. As a result, the Company presented $10,000 of unamortized debt issuance costs that had been included in “Other assets” on its condensed balance sheet as of June 30, 2016 as a direct deduction from the carrying amounts of the related long-term debt liability.    In July 2015, FASB issued ASU 2015-11, “Inventory (Topic 330) Related to Simplifying the Measurement of Inventory,” which applies to all inventory except that which is measured using last-in, first-out (“LIFO”) or the retail inventory method. Inventory measured using first-in, first-out (“FIFO”) or average cost is within the scope of the new guidance and should be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The amendments will be effective for public business entities for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The new guidance should be applied prospectively, and earlier application is permitted as of the beginning of an interim or annual reporting period. The Company is evaluating the impact of the standard on its financial statements.   In February 2016, FASB issued ASU 2016-02, “Leases.” This standard requires the recognition of all lease transactions with terms in excess of 12 months on the balance sheet as a lease liability and a right-of-use asset (as defined in the standard). ASU 2016-02 will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with earlier application permitted.  Upon adoption, the lessee will apply the new standard retrospectively to all periods presented or retrospectively using a cumulative effect adjustment in the year of adoption. The Company is currently assessing the effect the standard will have on its financial statements.   In March 2016, FASB issued ASU 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,” which reduces complexity in accounting standards related to share-based payment transactions, including, among others, (1) accounting for income taxes, (2) classification of excess tax benefits on the statement of cash flow, (3) forfeitures, and (4) statutory tax withholding requirements.  The ASU will be effective for annual reporting periods beginning on or after December 15, 2016, and interim periods within those annual periods, with earlier application permitted.  The Company is evaluating the impact of the standard on its financial statements.   Reclassifications: Certain items in the Company’s financial statements for fiscal 2016 have been reclassified to be consistent with the classifications adopted for the Company’s fiscal quarter ended December 31, 2016. The fiscal 2016 reclassifications are specific to the adoption of ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs” and had no impact on previously reported net income or equity.

Reclassifications: Certain items in the Company’s financial statements for fiscal 2016 have been reclassified to be consistent with the classifications adopted for the Company’s fiscal quarter ended December 31, 2016. The fiscal 2016 reclassifications are specific to the adoption of ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs” and had no impact on previously reported net income or equity.

Note 2.          Inventories   The components of inventory were approximately as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1px solid; text-align: center">December 31, 2016</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1px solid; text-align: center">June 30, 2016</td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="width: 74%; text-align: left; font: 10pt Times New Roman, Times, Serif">Parts inventory</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">1,877,000</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">1,615,000</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Work in process</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">149,000</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">165,000</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Finished goods</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">705,000</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">850,000</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Less: Reserve for obsolescence</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif">(160,000</td><td style="text-align: left; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif">(150,000</td><td style="text-align: left; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">Total</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif">2,571,000</td><td style="text-align: left; border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif">2,480,000</td><td style="text-align: left; border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>

Note 3.          Finite-life Intangible Assets   The carrying value of patents and trademarks includes the original cost of obtaining the patents, periodic renewal fees, and other costs associated with maintaining and defending patent and trademark rights. Patents and trademarks are amortized over their estimated useful lives, generally 15 and 12 years, respectively. During the six months ended December 31, 2016 and the year ended June 30, 2016, the Company abandoned certain domestic and foreign patents with net values of approximately $111,000 and $18,000, respectively, which was included as an expense in selling, general and administrative expense on the statements of operations. The majority of the pending patents, that were abandoned, related to the initial development of our SQL SmartVest technology and during a review of the Company’s patent portfolio it was determined that certain patents proved redundant to a subsequent SQL patent filing and were therefore abandoned. A smaller portion of expense was related to patents that covered technology that management considered outdated, and was no longer in use. Accumulated amortization was $789,000 and $820,000 at December 31, 2016 and June 30, 2016, respectively.    The activity and balances of finite-life intangible assets were approximately as follows:   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1px solid">December 31, 2016</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1px solid">June 30, 2016</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="width: 68%; font: 10pt Times New Roman, Times, Serif; text-align: left">Balance, beginning</td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">904,000</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,000,000</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in">Additions</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">45,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">45,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in">Abandonments</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(112,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(18,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Amortization expense</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1px solid"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1px solid">(61,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1px solid">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1px solid"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1px solid">(123,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1px solid">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">Balance, ending</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 3px double">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 3px double">776,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 3px double"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 3px double">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 3px double">904,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 3px double"> </td></tr> </table>

Note 4.          Warranty Liability   The Company provides a lifetime warranty on its products to the prescribed patient for sales within the U.S. and a three-year warranty for all institutional sales and sales to individuals outside the U.S. The Company estimates the costs that may be incurred under its warranty and records a liability in the amount of such costs at the time the product is shipped. Factors that affect the Company’s warranty liability include the number of units shipped, historical and anticipated rates of warranty claims, the product’s useful life and cost per claim. The Company periodically assesses the adequacy of its recorded warranty liability and adjusts the amounts as necessary.   Changes in the Company’s warranty liability were approximately as follows:   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Six Months Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fiscal Year Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1px solid"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1px solid">December 31, 2016</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1px solid"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1px solid"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1px solid">June 30, 2016</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1px solid"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="width: 68%; font: 10pt Times New Roman, Times, Serif; text-align: left">Beginning warranty reserve</td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">660,000</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">660,000</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Accrual for products sold</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">70,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">152,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Expenditures and costs incurred for warranty claims</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1px solid"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1px solid">(70,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1px solid">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1px solid"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1px solid">(152,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1px solid">)</td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">Ending warranty reserve</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 3px double">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 3px double">660,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 3px double"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 3px double">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 3px double">660,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 3px double"> </td></tr> </table>

Changes in the Company’s warranty liability were approximately as follows:   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Six Months Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fiscal Year Ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1px solid"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1px solid">December 31, 2016</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1px solid"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1px solid"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1px solid">June 30, 2016</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1px solid"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="width: 68%; font: 10pt Times New Roman, Times, Serif; text-align: left">Beginning warranty reserve</td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">660,000</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">660,000</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Accrual for products sold</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">70,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">152,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Expenditures and costs incurred for warranty claims</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1px solid"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1px solid">(70,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1px solid">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1px solid"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1px solid">(152,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1px solid">)</td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">Ending warranty reserve</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 3px double">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 3px double">660,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 3px double"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 3px double">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 3px double">660,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 3px double"> </td></tr> </table>

Note 5.          Income Taxes   On a quarterly basis, the Company estimates its effective tax rate for the full fiscal year and records a quarterly income tax provision based on the anticipated rate. As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction. Income tax expense was estimated at approximately $351,000 and the effective tax rate was 35.6% for the six months ended December 31, 2016. Estimated income tax expense for the six months ended December 31, 2016 includes a recognized tax benefit of approximately $22,000 as a result of the lapse of the statute of limitation on uncertain tax positions, which reduced the effective tax rate by 2.2% for that period.   Income tax expense was estimated at approximately $388,000 and the effective tax rate was 21.6% for the six months ended December 31, 2015. Estimated income tax expense during the six months ended December 31, 2015 includes a current tax expense of $682,000 and a discrete tax benefit of $294,000 due primarily to the Company’s release of the full valuation allowance against all of its net U.S. federal and state deferred tax assets.

Note 6.          Financing Arrangements   The Company has a credit facility that provides for a revolving line of credit and a term loan.  Effective December 18, 2016, the Company renewed its $2,500,000 revolving line of credit. There was no outstanding principal balance on the line of credit as of December 31, 2016 or June 30, 2016. Interest on borrowings under the line of credit, if any, would accrue at the prime rate (3.75% at December 31, 2016) and is payable monthly. The amount eligible for borrowing on the line of credit is limited to the lesser of $2,500,000 or 57.00% of eligible accounts receivable and the line of credit expires on December 18, 2017, if not renewed. At December 31, 2016, the maximum $2,500,000 was eligible for borrowing. The line of credit is secured by a security interest in substantially all of the tangible and intangible assets of the Company.   In connection with the credit facility, the Company also has a term loan, which had an outstanding principal balance of approximately $1,178,000 at December 31, 2016 and $1,200,000 as of June 30, 2016. The term loan was refinanced effective December 18, 2016, reducing the interest rate from 5.00% to 3.88%. The unamortized debt issuance cost associated with this debt was approximately $8,000 and $10,000 as of December 31, 2016 and June 30, 2016, respectively. The term loan bears interest at 3.88%, with monthly payments of principal and interest of approximately $7,900 and a final payment of principal and interest of approximately $1,085,000 due on the maturity date of December 18, 2018. Payment obligations under the term loan are secured by a mortgage on the Company’s real property.     The documents governing the line of credit and term loan contain certain financial and nonfinancial covenants that include a minimum tangible net worth covenant of not less than $10,125,000 and restrictions on the Company’s ability to incur certain additional indebtedness or pay dividends.

Note 7.          Stock-Based Compensation   The Company recorded approximately $235,000 and $109,000 of compensation expense related to current and past grants of stock options and restricted stock for the six months ended December 31, 2016 and 2015, respectively. This expense is included in selling, general and administrative expense. As of December 31, 2016, approximately $537,000 of total unrecognized compensation expense related to non-vested equity awards is expected to be recognized over a weighted average period of approximately 1.2 years.   The Company recognizes compensation expense related to share-based payment transactions in the financial statements based on the estimated fair value of the award issued. The fair value of each option is estimated using the Black-Scholes pricing model at the time of award grant. The Company estimates the expected life of options based on the expected holding period by the option holder. The risk-free interest rate is based upon observed U.S. Treasury interest rates for the expected term of the options. The Company makes assumptions with respect to expected stock price volatility based upon the volatility of its stock price. Forfeitures are estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from initial estimates. Forfeitures are estimated based on the percentage of awards expected to vest, taking into consideration the seniority level of the award recipient.   The following assumptions were used to estimate the fair value of options granted:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="width: 74%; text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Six Months Ended December 31, 2016</td> <td style="width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Fiscal Year Ended June 30, 2016</td></tr> <tr style="background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">Risk-free interest rate </td> <td style="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">1.14% - 1.27%</td> <td style="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">1.40% - 1.92%</td></tr> <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">Expected term (years) </td> <td style="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">6</td> <td style="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">6</td></tr> <tr style="background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">Expected volatility </td> <td style="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">100.5% - 105.8%</td> <td style="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">89.3% - 93.1%</td></tr> </table>   Stock Options   The Company issued 176,500 stock options pursuant to its 2014 Stock Compensation Plan during the six months ended December 31, 2016. Stock option transactions during the six months ended December 31, 2016 are summarized as follows: <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average</td></tr> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1px solid">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1px solid">Exercise Price per Share</td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="width: 68%; font: 10pt Times New Roman, Times, Serif">Outstanding at June 30, 2016</td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">599,800</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: center">$2.62</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">176,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$3.91</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Cancelled or Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1px solid"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1px solid">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1px solid"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">Outstanding at December 31, 2016</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 3px double"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 3px double">776,300</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 3px double"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$2.92</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>   The intrinsic value of an option is the amount by which the fair value of the underlying stock exceeds its exercise price. At December 31, 2016, the weighted average remaining contractual term for all outstanding stock options was 5.93 years and their aggregate intrinsic value was approximately $763,000. Outstanding at December 31, 2016 were 776,300 stock options issued to employees, of which approximately 467,000 were exercisable and had an aggregate intrinsic value of approximately $508,000.   Restricted Stock   The Company’s 2014 Stock Compensation Plan permits the grant of other stock-based awards. Historically, the Company makes restricted stock grants to key employees and non-employee directors that vest over six months to three years.    During the six months ended December 31, 2016, the Company issued restricted stock awards to employees totaling 30,000 shares of common stock, with a vesting term of one to three years and a fair value of $3.82 per share and to directors totaling 13,055 shares of common stock, with a vesting term of six months and a fair value of $3.83 per share. The restricted stock’s fair value per share represents the closing price of its common stock on the date of the grant. Restricted stock transactions during the six months ended December 31, 2016 are summarized as follows:   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="width: 68%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: center; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: center; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif">Number of Shares</td> <td style="width: 1%; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: center; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: center; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif">Weighted Average Grant Date Fair Value per Share</td> <td style="width: 1%; text-align: center; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">Unvested shares at June 30, 2016</td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">19,999</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif">$1.80</td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Granted</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">43,055</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif">$3.82</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Vested</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">–</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif">–</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Forfeited</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif">–</td> <td style="border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif">–</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">Unvested at December 31, 2016</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif">63,054</td> <td style="border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif">$3.18</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>

The Company issued 176,500 stock options pursuant to its 2014 Stock Compensation Plan during the six months ended December 31, 2016. Stock option transactions during the six months ended December 31, 2016 are summarized as follows: <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average</td></tr> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1px solid">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1px solid">Exercise Price per Share</td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="width: 68%; font: 10pt Times New Roman, Times, Serif">Outstanding at June 30, 2016</td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">599,800</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: center">$2.62</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">176,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$3.91</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Cancelled or Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1px solid"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1px solid">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1px solid"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">Outstanding at December 31, 2016</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 3px double"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 3px double">776,300</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 3px double"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$2.92</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

Restricted stock transactions during the six months ended December 31, 2016 are summarized as follows:   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="width: 68%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: center; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: center; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif">Number of Shares</td> <td style="width: 1%; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: center; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: center; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif">Weighted Average Grant Date Fair Value per Share</td> <td style="width: 1%; text-align: center; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">Unvested shares at June 30, 2016</td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">19,999</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif">$1.80</td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Granted</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">43,055</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif">$3.82</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Vested</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">–</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif">–</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Forfeited</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif">–</td> <td style="border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif">–</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">Unvested at December 31, 2016</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif">63,054</td> <td style="border-bottom: Black 3px double; font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 10pt Times New Roman, Times, Serif">$3.18</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>

The following assumptions were used to estimate the fair value of options granted:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="width: 74%; text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Six Months Ended December 31, 2016</td> <td style="width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; border-bottom: Black 1px solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Fiscal Year Ended June 30, 2016</td></tr> <tr style="background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">Risk-free interest rate </td> <td style="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">1.14% - 1.27%</td> <td style="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">1.40% - 1.92%</td></tr> <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">Expected term (years) </td> <td style="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">6</td> <td style="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">6</td></tr> <tr style="background-color: rgb(214,243,232); font: 10pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">Expected volatility </td> <td style="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">100.5% - 105.8%</td> <td style="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">89.3% - 93.1%</td></tr> </table>

Note 8.          Commitments and Contingencies   The Company is occasionally involved in claims and disputes arising in the ordinary course of business. The Company insures its business risks where possible to mitigate the financial impact of individual claims, and establishes reserves for an estimate of any probable cost of settlement or other disposition.

EX-101.CAL 8 elmd-20161231_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 elmd-20161231_def.xml XBRL DEFINITION FILE EX-101.LAB 10 elmd-20161231_lab.xml XBRL LABEL FILE Award Type [Axis] Employee Stock Options [Member] Finite-Lived Intangible Assets by Major Class [Axis] Patents [Member] Trademarks [Member] Lender Name [Axis] Credit Facility [Member] Geographical [Axis] International [Member] Restricted Stock Awards [Member] Range [Axis] Maximum [Member] Minimum [Member] Long-term Debt, Type [Axis] Term Loan [Member] Employees Restricted Stock Awards [Member] Title of Individual [Axis] Directors [Member] Document And Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Entity Public Float Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current Assets Cash Accounts receivable (net of allowances for doubtful accounts of $45,000) Inventories Prepaid expenses and other current assets Income tax receivable Total current assets Property and equipment, net Finite-life intangible assets, net Other assets Deferred income taxes Total assets Liabilities and Shareholders' Equity Current Liabilities Current maturities of long-term debt Accounts payable Accrued compensation Warranty reserve Other accrued liabilities Total current liabilities Long-term debt, less current maturities and net of debt issuance costs Total liabilities Commitments and Contingencies Equity Common stock, $0.01 par value; authorized: 13,000,000 shares; 8,230,167 and 8,187,112 issued and outstanding at December 31, 2016 and June 30, 2016, respectively Additional paid-in capital Retained earnings Total shareholders' equity Total liabilities and shareholders' equity Accounts receivable, allowance for doubtful accounts Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Net revenues Cost of revenues Gross profit Operating expenses Selling, general and administrative Research and development Total operating expenses Operating income Interest expense, net of interest income of $3,603, $2,924, $6,969 and $3,548 respectively Net income before income taxes Income tax expense Net income Income per share: Basic Diluted Weighted-average common shares outstanding: Basic Diluted Interest income Statement of Cash Flows [Abstract] Cash Flows From Operating Activities Net income Adjustments to reconcile net income to net cash provided by operating activities: Depreciation Amortization of finite-life intangible assets Amortization of debt issuance costs Share-based compensation expense Deferred taxes Loss on disposal of property and equipment Loss on disposal of intangible assets Changes in operating assets and liabilities: Accounts receivable Inventories Prepaid expenses and other assets Accounts payable and accrued liabilities Net cash provided by operating activities Cash Flows From Investing Activities Expenditures for property and equipment Expenditures for finite-life intangible assets Net cash used in investing activities Cash Flows From Financing Activities Principal payments on long-term debt including capital lease obligations Payment of deferred financing costs Net cash used in financing activities Net increase (decrease) in cash Cash Beginning of period End of period Accounting Policies [Abstract] Interim Financial Reporting Inventory Disclosure [Abstract] Inventories Goodwill and Intangible Assets Disclosure [Abstract] Finite-life Intangible Assets Product Warranties Disclosures [Abstract] Warranty Liability Income Tax Disclosure [Abstract] Income Taxes Debt Disclosure [Abstract] Financing Arrangements Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock-Based Compensation Commitments and Contingencies Disclosure [Abstract] Commitments And Contingencies Organization, Consolidation and Presentation of Financial Statements [Abstract] Use of Estimates Net income per common share New Accounting Pronouncements Reclassifications Schedule Of Components Of Inventory Schedule Of Finite-life Intangible Assets Schedule of changes in warranty liability Schedule of assumptions used to estimate fair value of options Schedule of stock compensation plan activity Schedule of restricted stock awards activity Statement [Table] Statement [Line Items] Common stock equivalents excluded from calculation of diluted earnings per share Unamortized debt issuance costs Sales Parts inventory Work in process Finished goods Less: Reserve for obsolescence Total Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Estimated useful life Accumulated amortization Future amortization expense Abandoned patents Balance, beginning Additions Abandonments Amortization expense Balance, ending Warranty term for institional sales and sales outside U.S. Warranty reserve, beginning Accrual for products sold Expenditures and costs incurred for warranty claims Warranty reserve, ending Effective tax rate Income tax expense Deferred tax benefit Effective tax rate, change in uncertain tax positions Change in valuation allowance Current income tax expense Discrete tax benefit Maximum borrowing capacity Credit facility effective date Credit facility expiration date Effective interest rate Interest rate Borrowing capacity of eligible accounts receivable Borrowing capacity of eligible accounts receivable (percent) Principal loan amount Unamortized debt issuance cost Monthly payments of principal and interest Final payment of principal and interest Term loan maturity date Minimum tangible net worth to be maintained Award vesting period Unrecognized compensation expense Unrecognized compensation expense, period for recognition Weighted average remaining contractual term of options outstanding Options outstanding, intrinsic value EX-101.PRE 11 elmd-20161231_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Dec. 31, 2016	Feb. 03, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	Electromed, Inc.
Entity Central Index Key	0001488917
Document Type	10-Q
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		8,230,167
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2017

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Unaudited) - USD ($)	Dec. 31, 2016	Jun. 30, 2016
Current Assets
Cash	$ 4,821,504	$ 5,123,355
Accounts receivable (net of allowances for doubtful accounts of $45,000)	8,284,895	7,611,437
Inventories	2,570,850	2,480,443
Prepaid expenses and other current assets	425,855	419,616
Income tax receivable	2,896	192,685
Total current assets	16,106,000	15,827,536
Property and equipment, net	3,381,803	3,375,189
Finite-life intangible assets, net	776,091	904,033
Other assets	112,058	127,759
Deferred income taxes	330,000	343,000
Total assets	20,705,952	20,577,517
Current Liabilities
Current maturities of long-term debt	49,720	46,309
Accounts payable	466,863	589,225
Accrued compensation	724,504	1,489,798
Warranty reserve	660,000	660,000
Other accrued liabilities	455,747	287,194
Total current liabilities	2,356,834	3,072,526
Long-term debt, less current maturities and net of debt issuance costs	1,120,856	1,146,395
Total liabilities	3,477,690	4,218,921
Commitments and Contingencies
Equity
Common stock, $0.01 par value; authorized: 13,000,000 shares; 8,230,167 and 8,187,112 issued and outstanding at December 31, 2016 and June 30, 2016, respectively	82,302	81,871
Additional paid-in capital	13,783,754	13,549,551
Retained earnings	3,362,206	2,727,174
Total shareholders' equity	17,228,262	16,358,596
Total liabilities and shareholders' equity	$ 20,705,952	$ 20,577,517

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Dec. 31, 2016	Jun. 30, 2016
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 45,000	$ 45,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	13,000,000	13,000,000
Common stock, shares issued	8,230,167	8,187,112
Common stock, shares outstanding	8,230,167	8,187,112

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Net revenues	$ 6,372,243	$ 6,262,106	$ 11,917,606	$ 11,263,295
Cost of revenues	1,445,786	1,363,509	2,663,522	2,505,268
Gross profit	4,926,457	4,898,597	9,254,084	8,758,027
Operating expenses
Selling, general and administrative	4,096,197	3,591,934	7,784,107	6,824,653
Research and development	100,801	57,090	451,641	98,634
Total operating expenses	4,196,998	3,649,024	8,235,748	6,923,287
Operating income	729,459	1,249,573	1,018,336	1,834,740
Interest expense, net of interest income of $3,603, $2,924, $6,969 and $3,548 respectively	15,598	17,880	32,304	38,086
Net income before income taxes	713,861	1,231,693	986,032	1,796,654
Income tax expense	(270,000)	(164,000)	(351,000)	(388,000)
Net income	$ 443,861	$ 1,067,693	$ 635,032	$ 1,408,654
Income per share:
Basic	$ 0.05	$ 0.13	$ 0.08	$ 0.17
Diluted	$ 0.05	$ 0.13	$ 0.08	$ 0.17
Weighted-average common shares outstanding:
Basic	8,167,112	8,133,857	8,167,112	8,133,857
Diluted	8,426,996	8,195,389	8,440,698	8,185,196

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) (Parenthetical) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Interest income	$ 3,603	$ 2,924	$ 6,969	$ 3,548

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash Flows From Operating Activities
Net income	$ 635,032	$ 1,408,654
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	312,075	307,778
Amortization of finite-life intangible assets	60,963	61,272
Amortization of debt issuance costs	9,216	9,327
Share-based compensation expense	234,634	109,164
Deferred taxes	13,000	(288,000)
Loss on disposal of property and equipment		17,117
Loss on disposal of intangible assets	111,497	7,848
Changes in operating assets and liabilities:
Accounts receivable	(673,458)	(384,562)
Inventories	(53,894)	(290,582)
Prepaid expenses and other assets	196,835	57,843
Accounts payable and accrued liabilities	(807,188)	151,127
Net cash provided by operating activities	38,712	1,166,986
Cash Flows From Investing Activities
Expenditures for property and equipment	(267,117)	(181,290)
Expenditures for finite-life intangible assets	(44,518)	(17,790)
Net cash used in investing activities	(311,635)	(199,080)
Cash Flows From Financing Activities
Principal payments on long-term debt including capital lease obligations	(24,056)	(24,046)
Payment of deferred financing costs	(4,872)	(13,520)
Net cash used in financing activities	(28,928)	(37,566)
Net increase (decrease) in cash	(301,851)	930,340
Cash
Beginning of period	5,123,355	3,598,240
End of period	$ 4,821,504	$ 4,528,580

XML 18 R7.htm IDEA: XBRL DOCUMENT

Interim Financial Reporting

6 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Interim Financial Reporting

Note 1. Interim Financial Reporting

A summary of the Company’s significant accounting policies follows:

XML 19 R8.htm IDEA: XBRL DOCUMENT

Inventories

6 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

Inventories

Note 2. Inventories

The components of inventory were approximately as follows:

	December 31, 2016			June 30, 2016
Parts inventory	$	1,877,000		$	1,615,000
Work in process		149,000			165,000
Finished goods		705,000			850,000
Less: Reserve for obsolescence		(160,000	)		(150,000	)
Total	$	2,571,000		$	2,480,000

XML 20 R9.htm IDEA: XBRL DOCUMENT

Finite-life Intangible Assets

6 Months Ended

Dec. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Finite-life Intangible Assets

Note 3. Finite-life Intangible Assets

The activity and balances of finite-life intangible assets were approximately as follows:

	December 31, 2016			June 30, 2016
Balance, beginning	$	904,000		$	1,000,000
Additions		45,000			45,000
Abandonments		(112,000	)		(18,000	)
Amortization expense		(61,000	)		(123,000	)
Balance, ending	$	776,000		$	904,000

XML 21 R10.htm IDEA: XBRL DOCUMENT

Warranty Liability

6 Months Ended

Dec. 31, 2016

Product Warranties Disclosures [Abstract]

Warranty Liability

Note 4. Warranty Liability

Changes in the Company’s warranty liability were approximately as follows:

		Six Months Ended			Fiscal Year Ended
		December 31, 2016			June 30, 2016
Beginning warranty reserve	$	660,000		$	660,000
Accrual for products sold		70,000			152,000
Expenditures and costs incurred for warranty claims		(70,000	)		(152,000	)
Ending warranty reserve	$	660,000		$	660,000

XML 22 R11.htm IDEA: XBRL DOCUMENT

Income Taxes

6 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

Note 5. Income Taxes

XML 23 R12.htm IDEA: XBRL DOCUMENT

Financing Arrangements

6 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Financing Arrangements

Note 6. Financing Arrangements

XML 24 R13.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

6 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

Note 7. Stock-Based Compensation

The following assumptions were used to estimate the fair value of options granted:

	Six Months Ended December 31, 2016	Fiscal Year Ended June 30, 2016
Risk-free interest rate	1.14% - 1.27%	1.40% - 1.92%
Expected term (years)	6	6
Expected volatility	100.5% - 105.8%	89.3% - 93.1%

Stock Options

			Weighted Average
	Number of Shares		Exercise Price per Share
Outstanding at June 30, 2016		599,800		$2.62
Granted		176,500		$3.91
Exercised		–		–
Cancelled or Forfeited		–		–
Outstanding at December 31, 2016		776,300		$2.92

Restricted Stock

	Number of Shares	Weighted Average Grant Date Fair Value per Share
Unvested shares at June 30, 2016	19,999	$1.80
Granted	43,055	$3.82
Vested	–	–
Forfeited	–	–
Unvested at December 31, 2016	63,054	$3.18

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 25 R14.htm IDEA: XBRL DOCUMENT

Commitments And Contingencies

6 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments And Contingencies

Note 8. Commitments and Contingencies

XML 26 R15.htm IDEA: XBRL DOCUMENT

Interim Financial Reporting (Policies)	6 Months Ended
Interim Financial Reporting (Policies)	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Use of Estimates	Use of estimates: Management uses estimates and assumptions in preparing the condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its condensed financial statements include revenue recognition and the related estimation of selling price adjustments, allowance for doubtful accounts, inventory obsolescence, share-based compensation, income taxes and the warranty reserve.
Net income per common share	Net income per common share: Net income is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using the weighted average number of common shares outstanding during the period, excluding any restricted stock awards which have not vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock options were exercised and converted into common stock at the beginning of the period, unless their effect would be anti-dilutive. Common stock equivalents excluded from the calculation of diluted earnings per share because their impact was anti-dilutive was 196,500 for the three and six months ended December 31, 2016 and 305,800 for the three and six months ended December 31, 2015.
New Accounting Pronouncements	New accounting pronouncements: In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance creating Accounting Standards Codification (“ASC”) Section 606, “Revenue from Contracts with Customers.” The new section will replace ASC Section 605, “Revenue Recognition” and creates modifications to various other revenue accounting standards for specialized transactions and industries. The section is intended to conform revenue accounting principles with a concurrently issued International Financial Reporting Standards with previously differing treatment between U.S. practice and that of much of the rest of the world, as well as to enhance disclosures related to disaggregated revenue information. Entities will have the option to apply the standard retrospectively to all prior periods presented, or to apply it retrospectively only to contracts existing at the effective date, with the cumulative effect of the standard recorded as an adjustment to beginning retained earnings. In August 2015, the FASB issued Accounting Standards Update (“ASU”) 2015-14 which delayed the effective date of the new revenue recognition guidance by one year. The updated guidance will be effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within that year. The Company is evaluating the impact of this standard on its financial statements. In April 2015, FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs.” This standard became effective on July 1, 2016 for the Company and requires that debt issuance costs be presented as a direct deduction from the carrying amount of long-term debt on the balance sheet. The new guidance aligns the presentation of debt issuance costs with debt discounts and premiums. The Company adopted this guidance retrospectively effective as of July 1, 2016. As a result, the Company presented $10,000 of unamortized debt issuance costs that had been included in “Other assets” on its condensed balance sheet as of June 30, 2016 as a direct deduction from the carrying amounts of the related long-term debt liability. In July 2015, FASB issued ASU 2015-11, “Inventory (Topic 330) Related to Simplifying the Measurement of Inventory,” which applies to all inventory except that which is measured using last-in, first-out (“LIFO”) or the retail inventory method. Inventory measured using first-in, first-out (“FIFO”) or average cost is within the scope of the new guidance and should be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The amendments will be effective for public business entities for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The new guidance should be applied prospectively, and earlier application is permitted as of the beginning of an interim or annual reporting period. The Company is evaluating the impact of the standard on its financial statements. In February 2016, FASB issued ASU 2016-02, “Leases.” This standard requires the recognition of all lease transactions with terms in excess of 12 months on the balance sheet as a lease liability and a right-of-use asset (as defined in the standard). ASU 2016-02 will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with earlier application permitted. Upon adoption, the lessee will apply the new standard retrospectively to all periods presented or retrospectively using a cumulative effect adjustment in the year of adoption. The Company is currently assessing the effect the standard will have on its financial statements. In March 2016, FASB issued ASU 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,” which reduces complexity in accounting standards related to share-based payment transactions, including, among others, (1) accounting for income taxes, (2) classification of excess tax benefits on the statement of cash flow, (3) forfeitures, and (4) statutory tax withholding requirements. The ASU will be effective for annual reporting periods beginning on or after December 15, 2016, and interim periods within those annual periods, with earlier application permitted. The Company is evaluating the impact of the standard on its financial statements.
Reclassifications	Reclassifications: Certain items in the Company’s financial statements for fiscal 2016 have been reclassified to be consistent with the classifications adopted for the Company’s fiscal quarter ended December 31, 2016. The fiscal 2016 reclassifications are specific to the adoption of ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs” and had no impact on previously reported net income or equity.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

6 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

Schedule Of Components Of Inventory

The components of inventory were approximately as follows:

	December 31, 2016			June 30, 2016
Parts inventory	$	1,877,000		$	1,615,000
Work in process		149,000			165,000
Finished goods		705,000			850,000
Less: Reserve for obsolescence		(160,000	)		(150,000	)
Total	$	2,571,000		$	2,480,000

XML 28 R17.htm IDEA: XBRL DOCUMENT

Finite-life Intangible Assets (Tables)

6 Months Ended

Dec. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule Of Finite-life Intangible Assets

The activity and balances of finite-life intangible assets were approximately as follows:

	December 31, 2016			June 30, 2016
Balance, beginning	$	904,000		$	1,000,000
Additions		45,000			45,000
Abandonments		(112,000	)		(18,000	)
Amortization expense		(61,000	)		(123,000	)
Balance, ending	$	776,000		$	904,000

XML 29 R18.htm IDEA: XBRL DOCUMENT

Warranty Liability (Tables)

6 Months Ended

Dec. 31, 2016

Product Warranties Disclosures [Abstract]

Schedule of changes in warranty liability

Changes in the Company’s warranty liability were approximately as follows:

		Six Months Ended			Fiscal Year Ended
		December 31, 2016			June 30, 2016
Beginning warranty reserve	$	660,000		$	660,000
Accrual for products sold		70,000			152,000
Expenditures and costs incurred for warranty claims		(70,000	)		(152,000	)
Ending warranty reserve	$	660,000		$	660,000

XML 30 R19.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

6 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of assumptions used to estimate fair value of options

The following assumptions were used to estimate the fair value of options granted:

	Six Months Ended December 31, 2016	Fiscal Year Ended June 30, 2016
Risk-free interest rate	1.14% - 1.27%	1.40% - 1.92%
Expected term (years)	6	6
Expected volatility	100.5% - 105.8%	89.3% - 93.1%

Schedule of stock compensation plan activity

			Weighted Average
	Number of Shares		Exercise Price per Share
Outstanding at June 30, 2016		599,800		$2.62
Granted		176,500		$3.91
Exercised		–		–
Cancelled or Forfeited		–		–
Outstanding at December 31, 2016		776,300		$2.92

Schedule of restricted stock awards activity

Restricted stock transactions during the six months ended December 31, 2016 are summarized as follows:

	Number of Shares	Weighted Average Grant Date Fair Value per Share
Unvested shares at June 30, 2016	19,999	$1.80
Granted	43,055	$3.82
Vested	–	–
Forfeited	–	–
Unvested at December 31, 2016	63,054	$3.18

XML 31 R20.htm IDEA: XBRL DOCUMENT

Interim Financial Reporting (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2016
Common stock equivalents excluded from calculation of diluted earnings per share	196,500	305,800	196,500	305,800
Unamortized debt issuance costs					$ 10,000
International [Member]
Sales			$ 332,000	$ 352,000

XML 32 R21.htm IDEA: XBRL DOCUMENT

Inventories (Details) - USD ($)	Dec. 31, 2016	Jun. 30, 2016
Inventory Disclosure [Abstract]
Parts inventory	$ 1,877,000	$ 1,615,000
Work in process	149,000	165,000
Finished goods	705,000	850,000
Less: Reserve for obsolescence	(160,000)	(150,000)
Total	$ 2,570,850	$ 2,480,443

XML 33 R22.htm IDEA: XBRL DOCUMENT

Finite-life Intangible Assets (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	$ 789,000	$ 820,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	15 years
Abandoned patents	$ 111,000	$ 18,000
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	12 years

XML 34 R23.htm IDEA: XBRL DOCUMENT

Finite-life Intangible Assets (Details) - USD ($)	6 Months Ended		12 Months Ended
Finite-life Intangible Assets (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Balance, beginning	$ 904,033	$ 1,000,000	$ 1,000,000
Additions	22,000		45,000
Abandonments	(112,000)		(18,000)
Amortization expense	(60,963)	$ (61,272)	(123,000)
Balance, ending	$ 776,091		$ 904,033

XML 35 R24.htm IDEA: XBRL DOCUMENT

Warranty Liability (Details Narratives)	6 Months Ended
Warranty Liability (Details Narratives)	Dec. 31, 2016
Product Warranties Disclosures [Abstract]
Warranty term for institional sales and sales outside U.S.	3 years

XML 36 R25.htm IDEA: XBRL DOCUMENT

Warranty Liability (Details) - USD ($)	6 Months Ended	12 Months Ended
Warranty Liability (Details) - USD ($)	Dec. 31, 2016	Jun. 30, 2016
Product Warranties Disclosures [Abstract]
Warranty reserve, beginning	$ 660,000	$ 660,000
Accrual for products sold	70,000	152,000
Expenditures and costs incurred for warranty claims	(70,000)	(152,000)
Warranty reserve, ending	$ 660,000	$ 660,000

XML 37 R26.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
Income Taxes (Details Narrative) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Effective tax rate			35.60%	21.60%
Income tax expense	$ 270,000	$ 164,000	$ 351,000	$ 388,000
Deferred tax benefit			$ 22,000
Effective tax rate, change in uncertain tax positions			(2.20%)
Change in valuation allowance				0
Current income tax expense				682,000
Discrete tax benefit				$ (294,000)

XML 38 R27.htm IDEA: XBRL DOCUMENT

Financing Arrangements (Details Narrative) - USD ($)	6 Months Ended
Financing Arrangements (Details Narrative) - USD ($)	Dec. 31, 2016	Jun. 30, 2016
Term Loan [Member]
Interest rate	3.88%	5.00%
Principal loan amount	$ 1,178,000	$ 1,200,000
Unamortized debt issuance cost	8,000	$ 10,000
Monthly payments of principal and interest	7,900
Final payment of principal and interest	$ 1,085,000
Term loan maturity date	Dec. 18, 2018
Minimum tangible net worth to be maintained	$ 10,125,000
Credit Facility [Member]
Maximum borrowing capacity	$ 2,500,000
Credit facility effective date	Dec. 18, 2016
Credit facility expiration date	Dec. 18, 2017
Effective interest rate	3.75%
Borrowing capacity of eligible accounts receivable	$ 2,500,000
Borrowing capacity of eligible accounts receivable (percent)	57.00%

XML 39 R28.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details Narrative) - USD ($)	6 Months Ended
Stock-Based Compensation (Details Narrative) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Share-based compensation expense	$ 234,634	$ 109,164
Unrecognized compensation expense	$ 537,000
Unrecognized compensation expense, period for recognition	1 year 2 months 12 days
Employee Stock Options [Member]
Weighted average remaining contractual term of options outstanding	5 years 11 months 4 days
Options outstanding, intrinsic value	$ 763,000
Options exercisable	467,000
Options exercisable, intrinsic value	$ 508,000
Restricted Stock Awards [Member]
Granted	43,055
Fair value of restricted stock granted	$ 3.82
Restricted Stock Awards [Member] \| Directors [Member]
Award vesting period	6 months
Granted	13,055
Fair value of restricted stock granted	$ 3.18
Restricted Stock Awards [Member] \| Minimum [Member]
Award vesting period	6 months
Restricted Stock Awards [Member] \| Maximum [Member]
Award vesting period	3 years
Employees Restricted Stock Awards [Member]
Granted	30,000
Fair value of restricted stock granted	$ 3.82
Employees Restricted Stock Awards [Member] \| Minimum [Member]
Award vesting period	1 year
Employees Restricted Stock Awards [Member] \| Maximum [Member]
Award vesting period	3 years

XML 40 R29.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details) - Employee Stock Options [Member]	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016
Risk free interest rate - minimum	1.14%	1.40%
Risk free interest rate - maximum	1.27%	1.92%
Expected term (year)	6 years	6 years
Expected volatility - minimum	100.50%	89.30%
Expected volatility - maximum	105.80%	93.10%

XML 41 R30.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details 1) - Employee Stock Options [Member]	6 Months Ended
	Dec. 31, 2016 $ / shares shares
Number of Shares
Options outstanding, beginning \| shares	599,800
Granted \| shares	176,500
Options outstanding, ending \| shares	776,300
Weighted Average Exercise Price
Options outstanding, beginning \| $ / shares	$ 2.62
Granted \| $ / shares	3.91
Options outstanding, ending \| $ / shares	$ 2.92

XML 42 R31.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details 2) - Restricted Stock Awards [Member]	6 Months Ended
	Dec. 31, 2016 $ / shares shares
Number of Shares
Outstanding, beginning \| shares	19,999
Granted \| shares	43,055
Outstanding, ending \| shares	63,054
Weighted Average Grant Date Fair Value
Outstanding, beginning \| $ / shares	$ 1.80
Granted \| $ / shares	3.82
Outstanding, ending \| $ / shares	$ 3.18

EXCEL 43 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 44 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 45 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.6.0.2 html 33 150 1 false 11 0 false 4 false false R1.htm 00000001 - Document - Document And Entity Information Sheet http://electromed.com/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets (Unaudited) Sheet http://electromed.com/role/BalanceSheets Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) Sheet http://electromed.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://electromed.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical) Sheet http://electromed.com/role/StatementsOfOperationsParenthetical Condensed Statements of Operations (Unaudited) (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://electromed.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Interim Financial Reporting Sheet http://electromed.com/role/InterimFinancialReporting Interim Financial Reporting Notes 7 false false R8.htm 00000008 - Disclosure - Inventories Sheet http://electromed.com/role/DisclosureInventories Inventories Notes 8 false false R9.htm 00000009 - Disclosure - Finite-life Intangible Assets Sheet http://electromed.com/role/Finite-lifeIntangibleAssets Finite-life Intangible Assets Notes 9 false false R10.htm 00000010 - Disclosure - Warranty Liability Sheet http://electromed.com/role/WarrantyLiability Warranty Liability Notes 10 false false R11.htm 00000011 - Disclosure - Income Taxes Sheet http://electromed.com/role/DisclosureIncomeTaxes Income Taxes Notes 11 false false R12.htm 00000012 - Disclosure - Financing Arrangements Sheet http://electromed.com/role/DisclosureFinancingArrangementsAndSubsequentEvent Financing Arrangements Notes 12 false false R13.htm 00000013 - Disclosure - Stock-Based Compensation Sheet http://electromed.com/role/Stock-basedCompensation Stock-Based Compensation Notes 13 false false R14.htm 00000014 - Disclosure - Commitments And Contingencies Sheet http://electromed.com/role/CommitmentsAndContingencies Commitments And Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Interim Financial Reporting (Policies) Sheet http://electromed.com/role/InterimFinancialReportingPolicies Interim Financial Reporting (Policies) Policies 15 false false R16.htm 00000016 - Disclosure - Inventories (Tables) Sheet http://electromed.com/role/DisclosureInventoriesTables Inventories (Tables) Tables http://electromed.com/role/DisclosureInventories 16 false false R17.htm 00000017 - Disclosure - Finite-life Intangible Assets (Tables) Sheet http://electromed.com/role/Finite-lifeIntangibleAssetsTables Finite-life Intangible Assets (Tables) Tables http://electromed.com/role/Finite-lifeIntangibleAssets 17 false false R18.htm 00000018 - Disclosure - Warranty Liability (Tables) Sheet http://electromed.com/role/WarrantyLiabilityTables Warranty Liability (Tables) Tables http://electromed.com/role/WarrantyLiability 18 false false R19.htm 00000019 - Disclosure - Stock-Based Compensation (Tables) Sheet http://electromed.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://electromed.com/role/Stock-basedCompensation 19 false false R20.htm 00000020 - Disclosure - Interim Financial Reporting (Details Narrative) Sheet http://electromed.com/role/InterimFinancialReportingDetailsNarrative Interim Financial Reporting (Details Narrative) Details http://electromed.com/role/InterimFinancialReportingPolicies 20 false false R21.htm 00000021 - Disclosure - Inventories (Details) Sheet http://electromed.com/role/DisclosureInventoriesDetails Inventories (Details) Details http://electromed.com/role/DisclosureInventoriesTables 21 false false R22.htm 00000022 - Disclosure - Finite-life Intangible Assets (Details Narrative) Sheet http://electromed.com/role/Finite-lifeIntangibleAssetsDetailsNarrative Finite-life Intangible Assets (Details Narrative) Details http://electromed.com/role/Finite-lifeIntangibleAssetsTables 22 false false R23.htm 00000023 - Disclosure - Finite-life Intangible Assets (Details) Sheet http://electromed.com/role/Finite-lifeIntangibleAssetsDetails Finite-life Intangible Assets (Details) Details http://electromed.com/role/Finite-lifeIntangibleAssetsTables 23 false false R24.htm 00000024 - Disclosure - Warranty Liability (Details Narratives) Sheet http://electromed.com/role/WarrantyLiabilityDetailsNarratives Warranty Liability (Details Narratives) Details http://electromed.com/role/WarrantyLiabilityTables 24 false false R25.htm 00000025 - Disclosure - Warranty Liability (Details) Sheet http://electromed.com/role/WarrantyLiabilityDetails Warranty Liability (Details) Details http://electromed.com/role/WarrantyLiabilityTables 25 false false R26.htm 00000026 - Disclosure - Income Taxes (Details Narrative) Sheet http://electromed.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://electromed.com/role/DisclosureIncomeTaxes 26 false false R27.htm 00000027 - Disclosure - Financing Arrangements (Details Narrative) Sheet http://electromed.com/role/DisclosureFinancingArrangementsAndSubsequentEventNarrativeDetails Financing Arrangements (Details Narrative) Details http://electromed.com/role/DisclosureFinancingArrangementsAndSubsequentEvent 27 false false R28.htm 00000028 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://electromed.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://electromed.com/role/Stock-basedCompensationTables 28 false false R29.htm 00000029 - Disclosure - Stock-Based Compensation (Details) Sheet http://electromed.com/role/Stock-basedCompensationDetails Stock-Based Compensation (Details) Details http://electromed.com/role/Stock-basedCompensationTables 29 false false R30.htm 00000030 - Disclosure - Stock-Based Compensation (Details 1) Sheet http://electromed.com/role/Stock-basedCompensationDetails1 Stock-Based Compensation (Details 1) Details http://electromed.com/role/Stock-basedCompensationTables 30 false false R31.htm 00000031 - Disclosure - Stock-Based Compensation (Details 2) Sheet http://electromed.com/role/Stock-basedCompensationDetails2 Stock-Based Compensation (Details 2) Details http://electromed.com/role/Stock-basedCompensationTables 31 false false All Reports Book All Reports elmd-20161231.xml elmd-20161231.xsd elmd-20161231_cal.xml elmd-20161231_def.xml elmd-20161231_lab.xml elmd-20161231_pre.xml true true ZIP 49 0000897101-17-000185-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000897101-17-000185-xbrl.zip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end